iBio, Inc. (NYSE:IBIO) Director David Arkowitz Acquires 18,382 Shares of Stock

iBio, Inc. (NYSE:IBIO) Director David Arkowitz purchased 18,382 shares of iBio stock in a transaction that occurred on Friday, January 10th. The shares were bought at an average cost of $2.72 per share, for a total transaction of $49,999.04. Following the transaction, the director now directly owns 18,382 shares of the company’s stock, valued at $49,999.04. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

iBio Stock Performance

Shares of NYSE:IBIO opened at $2.48 on Tuesday. iBio, Inc. has a 1 year low of $1.02 and a 1 year high of $4.98. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.37 and a quick ratio of 3.37. The business’s 50 day simple moving average is $2.51 and its 200 day simple moving average is $2.29.

iBio (NYSE:IBIO) last released its earnings results on Tuesday, November 12th. The company reported ($0.46) earnings per share for the quarter, hitting the consensus estimate of ($0.46). On average, sell-side analysts anticipate that iBio, Inc. will post -1.74 earnings per share for the current fiscal year.

About iBio

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.